Mortality and Gross Pathology of Secondary Disease in Germfree Mouse Radiation Chimeras

Jones, Jan M.; Wilson, Robert A.; Bealmear, Patricia M.

doi:10.2307/3573066

Cited by 192 publications

(107 citation statements)

References 10 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…For instance, gnotobiotic mice have a lower risk of developing GVHD. 29,30 Furthermore, patients who are seropositive for 3-4 herpesviruses more often developed acute GVHD compared to those who are seropositive for 0-2 herpesviruses. 31 Storb et al 32 report that patients treated in LAF rooms were less likely to develop acute GVHD than those treated in regular hospital rooms.…”

Section: Discussionmentioning

confidence: 99%

Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

Svahn

Ringdén

Remberger

2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

Svahn

Ringdén

Remberger

2005

Bone Marrow Transplant

View full text Add to dashboard Cite

“…For instance, gnotobiotic mice have a lower risk of developing GVHD. 31,32 A clinical study showed that patients treated in laminar air flow rooms were less likely to develop GVHD than those treated in regular hospital rooms. 33 Because of the lower risk of GVHD in the home care group, TRM was also significantly lower in this group than in the controls (Figure 3, Tables 4 and 5).…”

Section: Discussionmentioning

confidence: 99%

Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care

Svahn

Remberger

Myrbäck

et al. 2002

Blood

141

136

View full text Add to dashboard Cite

After myeloablative treatment and allogeneic stem cell transplantation (SCT), patients are kept in isolation rooms in the hospital to prevent neutropenic infections. During a 3-year period, patients were given the option of treatment at home after SCT. Daily visits by an experienced nurse and daily phone calls from a physician from the unit were included in the protocol. We compared 36 patients who wished to be treated at home with 18 patients who chose hospital care (control group 1). A matched control group of 36 patients treated in the hospital served as control group 2. All home care patients had hematologic malignancies and 19 were in first remission or first chronic phase. Of the donors, 25 were unrelated. The patients spent a median of 16 days at home (range, 0-26 days). Before discharge to the outpatient clinic after SCT, patients spent a median of 4 days (range, 0-39 days) in the hospital. In the multivariate analysis, the home care patients were discharged earlier (relative risk [RR] 0.33, P ‫؍‬ .03), had fewer days on total parenteral nutrition (RR 0.24, P < .01), less acute graft-versus-host disease (GVHD) grades II-IV (RR 0.25, P ‫؍‬ .01), lower transplantationrelated mortality rates (RR 0.22, P ‫؍‬ .04), and lower costs (RR 0.37, P < .05), compared with the controls treated in the hospital. The 2-year survival rates were 70% in the home care group versus 51% and 57% (not significant) in the 2 control groups, respectively (P < .03). To conclude, home care after SCT is a novel and safe approach. This study found it to be advantageous, compared with hospital care. (Blood. 2002;100: 4317-4324)

show abstract

“…IL-2 may improve resistance to infection through the antiviral, antifungal, antiprotozoan, or antibacterial activities of activated NK cells (35,36), or by promoting the development of other immunocompetent cell populations; such activities might be highly protective, since infection has been found to play a pivotal role in the induction of, and morbidity from, GVHD (37,38). The ability of IL-2 to prevent GVHD mortality long after completion of such therapy suggests that protection is either due to the induction of a protective cell population by IL-2, or to the permanent deletion of GVH-reactive clones from the original allogeneic splenocyte inoculum.…”

Section: Discussionmentioning

confidence: 99%

In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.

Sykes

Romick

Hoyles

et al. 1990

The Journal of Experimental Medicine

View full text Add to dashboard Cite

Avoiding graft-vs .-host disease (GVHD)' while retaining the engraftment-promoting and antileukemic effects of T cells in allogeneic marrow remains a major challenge in the field of bone marrow transplantation (BMT). While T cell depletion reduces the incidence of GVHD, it is associated with an increased probability ofengraftment failure (1-6) and a greater risk ofleukemic relapse (4, 5, 7). Previous work from this laboratory has demonstrated that the GVHD-related mortality of lethally irradiated, bone marrow-reconstituted mice can be delayed by the coadministration of T cell-depleted (TCD) syngeneic marrow (8). Although this result was encouraging, we have found the magnitude ofthe protection from acute GVHD mortality to be limited, and no protection from chronic GVHD mortality has been apparent (8). We therefore sought a method of augmenting this protective effect of TCD syngeneic marrow. We have previously demonstrated that TCD syngeneic marrow is responsible for most of the natural suppressor (NS) activity arising in spleens of lethally irradiated mice reconstituted with a mixture of allogeneic plus syngeneic marrow, and have hypothesized that such cells might be responsible for the anti-GVHD effect of TCD syngeneic marrow (9). Since cell lines with in vitro NS activity and in vivo anti-GVHD effects have been successfully cultured in IL-2 (10, 11; Sykes M., K. A. Hoyles, M. L. Romick, and D. H. Sachs, manuscript in preparation), we wished to address the possibility that the administration of IL-2 in vivo to lethally irradiated, bone marrow-transplanted mice might increase the anti-GVHD effect of TCD syngeneic bone marrow. Our results indicate that IL-2 provides significant protection against GVHD mortality from allogeneic lymphocytes while permitting complete repopulation by allogeneic bone marrow cells (BMC). When suboptimal amounts of IL-2 were given, maximal protection was achieved when TCD syngeneic marrow was also administered . Survivors protected in this manner similarly demonstrated complete allogeneic reconstitution .

show abstract

Mortality and Gross Pathology of Secondary Disease in Germfree Mouse Radiation Chimeras

Cited by 192 publications

References 10 publications

Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care

In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.

Contact Info

Product

Resources

About